How to Navigate Uncertainty and Transformation in 2025, with the CFO of Trevi Therapeutics

Описание: Trevi Therapeutics is a clinical-stage biopharmaceutical company based in New Haven, Connecticut, developing a therapy for chronic cough in patients with pulmonary fibrosis and refractory chronic cough. In June 2025, Trevi announced positive topline results from its Phase 2b trial and closed an equity offering with proceeds of approximately $115 million.

Lisa Delfini is the CFO of Trevi Therapeutics, and has been in the role since 2021. She was previously Accounting and Advisory Services Partner at Marcum LLP, and held senior roles at GE, including Global Controller for GE Corporate’s Technical Center of Excellence and Global Controller for the GE Industrial Solutions division. She started her career at Deloitte & Touche LLP, becoming Client Service Partner by the end of her tenure.

Highlights:

(09:50):Trevi’s finance team has three goals: Ensuring the company is funded, ensuring the clinical development team has the financial information they need to make decisions, and maintaining compliance.
(15:00): Lisa cites three keys to a successful fundraise: A drug that works, a disciplined team that can execute drug development well, and a clear message that physicians, patients and investors can understand
(23:00): Over the last several years, the Trevi finance team has adopted a number of tools to modernize its financial operations, including Netsuite, FloQast, Cube, OptionTrax, and Auxilius.
(25:45):Trevi switched to managing clinical accruals and forecasts in Auxilius the information received from their CRO was no longer meeting their needs.
(31:45): In addition to managing clinical accruals in Auxilius, Trevi also manages its clinical trial forecasts on the platform, and uses Auxilius Investigator Reconciliation to identify duplicate billing and overbilling in their site payments.
(39:00): Lisa recommends aspiring CFOs seek out opportunities to build their presentation skills and get curious about the broader business outside the finance function.